Results 21 to 30 of about 83,780 (258)

Efficient lentiviral transduction method to gene modify cord blood CD8+ T cells for cancer therapy applications

Molecular Therapy: Methods & Clinical Development, 2021
Adoptive T cell therapy utilizing tumor-specific autologous T cells has shown promising results for cancer treatment. However, the limited numbers of autologous tumor-associated antigen (TAA)-specific T cells and the functional aberrancies, due to ...
Vania Lo Presti, Annelisa M. Cornel, Maud Plantinga, Ester Dünnebach, Jurgen Kuball, Jaap Jan Boelens, Stefan Nierkens, Niek P. van Til   +7 more
doaj   +1 more source

Fusogenic effects of murine retroviruses and cationic enhancers of transduction [PDF]

Cancer Gene Therapy, 2000
The maturation of retrovirus particles involves proteolytic cleavage of the envelope glycoprotein transmembrane component, resulting in conversion of the virus particle to a fusogenic or infectious state. Susceptible murine cells exposed to virus-containing supernatants from ecotropic retroviral helper cells occasionally fused to neighboring cells ...
G, Xu, F, Solaiman, M A, Zink, C P, Hodgson   +3 more
openaire   +2 more sources

The Optimized γ-Globin Lentiviral Vector GGHI-mB-3D Leads to Nearly Therapeutic HbF Levels In Vitro in CD34⁺ Cells from Sickle Cell Disease Patients

Viruses, 2022
We have previously demonstrated that both the original γ-globin lentiviral vector (LV) GGHI and the optimized GGHI-mB-3D LV, carrying the novel regulatory elements of the 3D HPFH-1 enhancer and the 3’ β-globin UTR, can significantly increase HbF ...
Ekati Drakopoulou, Maria Georgomanoli, Carsten W. Lederer, Fottes Panetsos, Marina Kleanthous, Ersi Voskaridou, Dimitrios Valakos, Eleni Papanikolaou, Nicholas P. Anagnou   +8 more
doaj   +1 more source

Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors

Molecular Therapy: Methods & Clinical Development, 2019
Chimeric antigen receptor (CAR)-modified T cells have revealed promising results in the treatment of cancer, but they still need to overcome various hurdles, including a complicated manufacturing process.
Arezoo Jamali, Laura Kapitza, Thomas Schaser, Ian C.D. Johnston, Christian J. Buchholz, Jessica Hartmann   +5 more
doaj   +1 more source

Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa [PDF]

European Cells & Materials, 2018
The combination of gene therapy and tissue engineering is one of the most promising strategies for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
A Dakiw Piaceski, D Larouche, K Ghani, F Bisson, S Cortez Ghio, S Larochelle, VJ Moulin, M Caruso, L Germain   +8 more
doaj   +1 more source

Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells [PDF]

Gene Therapy, 2005
The full realization of conditionally replicative adenoviruses (CRAds) for cancer therapy has been hampered by the limited knowledge of CRAd function in vivo and particularly in an immunocompetent host. To address this issue, we previously proposed a canine adenovirus type 2 (CAV2)-based CRAd for clinical evaluation in canine patients with osteosarcoma
L P, Le, A A, Rivera, J N, Glasgow, V V, Ternovoi, H, Wu, M, Wang, B F, Smith, G P, Siegal, D T, Curiel   +8 more
openaire   +2 more sources

Muscle fiber type-predominant promoter activity in lentiviral-mediated transgenic mouse. [PDF]

PLoS ONE, 2011
Variations in gene promoter/enhancer activity in different muscle fiber types after gene transduction was noticed previously, but poorly analyzed. The murine stem cell virus (MSCV) promoter drives strong, stable gene expression in hematopoietic stem ...
Tomohiro Suga, En Kimura, Yuka Morioka, Masahito Ikawa, Sheng Li, Katsuhisa Uchino, Yuji Uchida, Satoshi Yamashita, Yasushi Maeda, Jeffrey S Chamberlain, Makoto Uchino   +10 more
doaj   +1 more source

A lentiviral vector B cell gene therapy platform for the delivery of the anti-HIV-1 eCD4-Ig-knob-in-hole-reversed immunoadhesin

Molecular Therapy: Methods & Clinical Development, 2023
Barriers to effective gene therapy for many diseases include the number of modified target cells required to achieve therapeutic outcomes and host immune responses to expressed therapeutic proteins.
Eirini Vamva, Stosh Ozog, Daniel P. Leaman, Rene Yu-Hong Cheng, Nicholas J. Irons, Andee Ott, Claire Stoffers, Iram Khan, Geraldine K.E. Goebrecht, Matthew R. Gardner, Michael Farzan, David J. Rawlings, Michael B. Zwick, Richard G. James, Bruce E. Torbett   +14 more
doaj   +1 more source

Enhancing transduction of the liver by adeno-associated viral vectors [PDF]

Gene Therapy, 2008
A number of distinct factors acting at different stages of the adeno-associated virus vector (AAV)-mediated gene transfer process were found to influence murine hepatocyte transduction. Foremost among these was the viral capsid protein. Self-complementary (sc) AAV pseudotyped with capsid from serotype 8 or rh.10 mediated fourfold greater hepatocyte ...
Nathwani, A. C., Cochrane, M., McIntosh, J., Ng, C. Y. C., Zhou, J., Gray, J. T., Davidoff, A. M.   +6 more
openaire   +5 more sources

Optimization of lentiviral delivery of barcoded anti-CD20 chimeric antigen receptors into rhesus macaque and human natural killer cells

Molecular Therapy: Methods & Clinical Development
Natural killer (NK) cells are pivotal in immunosurveillance and hold great potential for immunotherapy due to their ability to target malignant cells. Their low risk of causing graft-versus-host disease (GvHD) post-allogenic transplantation underscores ...
Taha B. Hayal, Aman A. Mulla, David S.J. Allan, Brynn B. Duncan, Saanika Joshi, So Gun Hong, Rafet Basar, Katayoun Rezvani, Richard W. Childs, Chuanfeng Wu, Cynthia E. Dunbar   +10 more
doaj   +1 more source